Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

• Claire Corcoran,
• Sweta Rani,
• Susan Breslin,
• Martina Gogarty,
• Irene M Ghobrial,
• John Crown,
• Lorraine O’Driscoll

Affiliations

Claire Corcoran

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin

Sweta Rani

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin

Susan Breslin

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin

Martina Gogarty

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin

Irene M Ghobrial

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School

John Crown

Department of Oncology, St. Vincent’s University Hospital

Lorraine O’Driscoll

School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin